Senate Bill No. 191 establishes a psychedelic-assisted therapy pilot program to be administered by a medical school in Connecticut, effective July 1, 2026. The bill defines "MDMA" and "psilocybin," and introduces the term "qualified patient," which refers to individuals aged eighteen and older who meet specific clinical eligibility criteria set by the institutional review board of the administering medical school. This includes residents who are veterans, retired first responders, or direct care healthcare workers.

The bill also modifies the timeline for the establishment of the pilot program, replacing the previous requirement to start by January 1, 2023, with a directive for the Department of Mental Health and Addiction Services to implement the program within available appropriations. Additionally, the provision that mandated the cessation of the pilot program upon the approval of MDMA and psilocybin for medical use by the Drug Enforcement Administration has been removed. This allows the program to continue regardless of federal approval status.

Statutes affected:
Raised Bill:
PH Joint Favorable:
File No. 28:
Public Act No. 26-108: